IONS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

153.14M

-32.54%

-1.187

+175.71%

188.41M

+42.73%

-0.495

-46.46%

207.89M

-54.01%

-0.520

-161.45%

Estimates Revision

The market is revising Upward the revenue expectations for Ionis Pharmaceuticals, Inc. (IONS) for FY2025, with the revenue forecasts being adjusted by 4.06% over the past three months. During the same period, the stock price has changed by 16.04%.

Revenue Estimates for FY2025

Revise Upward

+4.06%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-13.7%

In Past 3 Month

Stock Price

Go Up

+16.04%

In Past 3 Month

17 Analyst Rating

Wall Street analysts forecast IONS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IONS is 84.33 USD with a low forecast of 65.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

14 Buy

3 Hold

0 Sell

Strong Buy

Current: 0.000

Low

65.00

Averages

84.33

High

110.00

Current: 0.000

Low

65.00

Averages

84.33

High

110.00

Wells Fargo

NULL

Overweight

upgrade

$82 -> $100

2026-01-05

New

Reason

Wells Fargo

Price Target

$82 -> $100

2026-01-05

New

upgrade

NULL

Overweight

Reason

Wells Fargo raised the firm's price target on Ionis Pharmaceuticals to $100 from $82 and keeps an Overweight rating on the shares. Following a strong 2025, the firm sees further value creation on multiple catalysts in 2026, including Phase 3 readouts for bepirovirsen in cHBV, pelacarsen in Lp(a) and WAINUA in ATTR-CM.

RBC Capital

Luca Issi

Outperform

maintain

$82 -> $95

2025-12-17

Reason

RBC Capital

Luca Issi

Price Target

$82 -> $95

2025-12-17

maintain

Outperform

Reason

RBC Capital analyst Luca Issi raised the firm's price target on Ionis Pharmaceuticals to $95 from $82 and keeps an Outperform rating on the shares. The company is poised to successfully transition to a fully integrated commercial organization as its Tryngolza is off to a good start in FCS, and the firm believes that recent data in sHTG will open up a much broader opportunity given a total addressable market of 1M patients in the US alone, the analyst tells investors in a research note.

BofA

Jason Gerberry

Buy

maintain

$86 -> $97

2025-12-09

Reason

BofA

Jason Gerberry

Price Target

$86 -> $97

2025-12-09

maintain

Buy

Reason

BofA analyst Jason Gerberry raised the firm's price target on Ionis Pharmaceuticals to $97 from $86 and keeps a Buy rating on the shares after having hosted fireside chats with management teams at the firm's CNS Therapeutics Conference.

H.C. Wainwright

Buy

maintain

$100 -> $110

2025-11-10

Reason

H.C. Wainwright

Price Target

$100 -> $110

2025-11-10

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Ionis Pharmaceuticals to $110 from $100 and keeps a Buy rating on the shares. The firm believes Olezarsen is positioned to become the new standard for severe hypertriglyceridemia.

Piper Sandler

Overweight

maintain

$70 -> $77

2025-11-04

Reason

Piper Sandler

Price Target

$70 -> $77

2025-11-04

maintain

Overweight

Reason

Piper Sandler raised the firm's price target on Ionis Pharmaceuticals to $77 from $70 and keeps an Overweight rating on the shares. The firm notes the company reported a solid Q3 print with total revenue of $157M, including $32M from Tryngolza sales. Piper commend this name's recent commercial execution and continue to like the set-up on shares given near- and intermediate-term portfolio expansion opportunities across wholly owned and partnered assets.

TD Cowen

Buy

upgrade

$59 -> $99

2025-10-30

Reason

TD Cowen

Price Target

$59 -> $99

2025-10-30

upgrade

Buy

Reason

TD Cowen raised the firm's price target on Ionis Pharmaceuticals to $99 from $59 and keeps a Buy rating on the shares. The firm updated its model following solid Q3 results driven by Tryngolza beat/raise. Cowen is adding $1.5B in peak global sales to theirmodel at $25k/yr.

Valuation Metrics

The current forward P/E ratio for Ionis Pharmaceuticals Inc (IONS.O) is -29.54, compared to its 5-year average forward P/E of -23.79. For a more detailed relative valuation and DCF analysis to assess Ionis Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-23.79

Current PE

-29.54

Overvalued PE

-4.25

Undervalued PE

-43.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-15.59

Current EV/EBITDA

-21.12

Overvalued EV/EBITDA

-9.46

Undervalued EV/EBITDA

-21.71

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

9.65

Current PS

16.79

Overvalued PS

11.93

Undervalued PS

7.38

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 242.57% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

IONS News & Events

Events Timeline

No data

News

9.0

01-07Newsfilter

PinnedIonis and GSK's Bepirovirsen Shows Significant Functional Cure Rate in Chronic Hepatitis B Trials

4.5

01-08Yahoo Finance

S&P 500 and Dow Reverse Gains as Nasdaq Narrows Upturn

4.5

01-08Yahoo Finance

S&P 500 and Dow Retreat from Highs, Eli Lilly and Google Flash Buy Signals

People Also Watch

Frequently Asked Questions

What is Ionis Pharmaceuticals Inc (IONS) stock price today?

The current price of IONS is 81.54 USD — it has decreased -1.96 % in the last trading day.

What is Ionis Pharmaceuticals Inc (IONS)'s business?

Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

What is the price predicton of IONS Stock?

What is Ionis Pharmaceuticals Inc (IONS)'s revenue for the last quarter?

Ionis Pharmaceuticals Inc revenue for the last quarter amounts to 156.72M USD, increased 17.12 % YoY.

What is Ionis Pharmaceuticals Inc (IONS)'s earnings per share (EPS) for the last quarter?

Ionis Pharmaceuticals Inc. EPS for the last quarter amounts to -0.80 USD, decreased -15.79 % YoY.

What changes have occurred in the market's expectations for Ionis Pharmaceuticals Inc (IONS)'s fundamentals?

How many employees does Ionis Pharmaceuticals Inc (IONS). have?

Ionis Pharmaceuticals Inc (IONS) has 1069 emplpoyees as of January 09 2026.

What is Ionis Pharmaceuticals Inc (IONS) market cap?

Today IONS has the market capitalization of 13.21B USD.